Biocon
Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach
EC approval follows recent U.S. FDA approval of Biocon's pertuzumab biosimilar Provides an additional treatment option for patients with…
